The effect of melatonin on the quality of sleep in COVID-19 patients

Phase 3

Recruiting

• Conditions: COVID-19.; Coronavirus infection, unspecified; B34.2

• Registration Number: IRCT20200411047030N1
• Lead Sponsor: Mazandaran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 18 May 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 82

Inclusion Criteria

Consent to attend the study
Clinical symptoms
Lymphocyte count less than 1100
Positive CT scan or C-reactive protein

Exclusion Criteria

Epilepsy
Taking warfarin and other anticoagulants and coagulation disorders
Uncontrolled diabetes and high blood pressure

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Stop the fever. Timepoint: It will be reviewed for 7 days from the study onset. Method of measurement: It is recorded by a thermometer.;Transfer to ICU. Timepoint: A maximum of 10 days of hospitalization will be checked. Method of measurement: Tracking hospitalized patients through questions and recording in questionnaires.;Mortality. Timepoint: A maximum of 10 days of hospitalization will be checked. Method of measurement: Tracking hospitalized patients through questions and recording in questionnaires.;Sleep quality. Timepoint: Days 1, 2, 3, and 7. Method of measurement: The Leeds Sleep Evaluation questionnaire will be used.

Secondary Outcome Measures

Name	Time	Method
ymphopenia status. Timepoint: It will be reviewed on the first day and day 7. Method of measurement: Cell counter device.;C-reactive protein status. Timepoint: It will be reviewed on the first day and day 7. Method of measurement: Serology test.;Peripheral capillary oxygen saturation (SPO2). Timepoint: It will be reviewed on the first day and day 7. Method of measurement: Pulse Oximeter.